177 related articles for article (PubMed ID: 15750833)
1. Induction of specific human primary immune responses to a Semliki Forest virus-based tumor vaccine in a Trimera mouse model.
Ni B; Gao W; Zhu B; Lin Z; Jia Z; Zhou W; Zhao J; Wang L; Wu Y
Cancer Immunol Immunother; 2005 May; 54(5):489-98. PubMed ID: 15750833
[TBL] [Abstract][Full Text] [Related]
2. A comparative study on the immunotherapeutic efficacy of recombinant Semliki Forest virus and adenovirus vector systems in a murine model for cervical cancer.
Riezebos-Brilman A; Walczak M; Regts J; Rots MG; Kamps G; Dontje B; Haisma HY; Wilschut J; Daemen T
Gene Ther; 2007 Dec; 14(24):1695-704. PubMed ID: 17928874
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis C virus non-structural protein 3-specific cellular immune responses following single or combined immunization with DNA or recombinant Semliki Forest virus particles.
Brinster C; Chen M; Boucreux D; Paranhos-Baccala G; Liljeström P; Lemmonier F; Inchauspé G
J Gen Virol; 2002 Feb; 83(Pt 2):369-381. PubMed ID: 11807230
[TBL] [Abstract][Full Text] [Related]
4. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene.
Colmenero P; Liljeström P; Jondal M
Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722
[TBL] [Abstract][Full Text] [Related]
5. [Construction of human MAGE-3 DNA vaccine and its immune effects observed in vivo].
Liu XE; Sun XD; Wu JM
Sheng Wu Gong Cheng Xue Bao; 2004 Mar; 20(2):165-9. PubMed ID: 15969102
[TBL] [Abstract][Full Text] [Related]
6. Naked RNA immunization with replicons derived from poliovirus and Semliki Forest virus genomes for the generation of a cytotoxic T cell response against the influenza A virus nucleoprotein.
Vignuzzi M; Gerbaud S; van der Werf S; Escriou N
J Gen Virol; 2001 Jul; 82(Pt 7):1737-1747. PubMed ID: 11413386
[TBL] [Abstract][Full Text] [Related]
7. [Preventive and therapeutic effect of genetic vaccine based on recombinant alpha virus against mouse mastocytoma P815].
Ni B; Yang RG; Li YQ; Wu YZ
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2004 Jan; 20(1):45-8. PubMed ID: 15182620
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo.
Ma JH; Sui YF; Ye J; Huang YY; Li ZS; Chen GS; Qu P; Song HP; Zhang XM
Cancer Immunol Immunother; 2005 Sep; 54(9):907-14. PubMed ID: 15756604
[TBL] [Abstract][Full Text] [Related]
9. Recombinant Semliki Forest virus vaccine vectors: the route of injection determines the localization of vector RNA and subsequent T cell response.
Colmenero P; Berglund P; Kambayashi T; Biberfeld P; Liljeström P; Jondal M
Gene Ther; 2001 Sep; 8(17):1307-14. PubMed ID: 11571567
[TBL] [Abstract][Full Text] [Related]
10. Induction of P815 tumor immunity by DNA-based recombinant Semliki Forest virus or replicon DNA expressing the P1A gene.
Ni B; Lin Z; Zhou L; Wang L; Jia Z; Zhou W; Diciommo DP; Zhao J; Bremner R; Wu Y
Cancer Detect Prev; 2004; 28(6):418-25. PubMed ID: 15582265
[TBL] [Abstract][Full Text] [Related]
11. Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.
Buchan S; Grønevik E; Mathiesen I; King CA; Stevenson FK; Rice J
J Immunol; 2005 May; 174(10):6292-8. PubMed ID: 15879128
[TBL] [Abstract][Full Text] [Related]
12. Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2.
Piechocki MP; Pilon SA; Wei WZ
J Immunol; 2001 Sep; 167(6):3367-74. PubMed ID: 11544327
[TBL] [Abstract][Full Text] [Related]
13. Recombinant Semliki Forest virus particles encoding the prME or NS1 proteins of louping ill virus protect mice from lethal challenge.
Fleeton MN; Sheahan BJ; Gould EA; Atkins GJ; Liljestr M P
J Gen Virol; 1999 May; 80 ( Pt 5)():1189-1198. PubMed ID: 10355766
[TBL] [Abstract][Full Text] [Related]
14. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
15. Comparative prime-boost vaccinations using Semliki Forest virus, adenovirus, and ALVAC vectors demonstrate differences in the generation of a protective central memory CTL response against the P815 tumor.
Näslund TI; Uyttenhove C; Nordström EK; Colau D; Warnier G; Jondal M; Van den Eynde BJ; Liljeström P
J Immunol; 2007 Jun; 178(11):6761-9. PubMed ID: 17513723
[TBL] [Abstract][Full Text] [Related]
16. The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination.
Ni J; Schirrmacher V; Fournier P
Vaccine; 2010 Oct; 28(42):6891-900. PubMed ID: 20709006
[TBL] [Abstract][Full Text] [Related]
17. Effective immunotherapy of cancer by DNA vaccination.
Park JH; Kim CJ; Lee JH; Shin SH; Chung GH; Jang YS
Mol Cells; 1999 Aug; 9(4):384-91. PubMed ID: 10515601
[TBL] [Abstract][Full Text] [Related]
18. Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity.
Yang S; Vervaert CE; Burch J; Grichnik J; Seigler HF; Darrow TL
Int J Cancer; 1999 Nov; 83(4):532-40. PubMed ID: 10508491
[TBL] [Abstract][Full Text] [Related]
19. Genetic vaccination against the melanocyte lineage-specific antigen gp100 induces cytotoxic T lymphocyte-mediated tumor protection.
Schreurs MW; de Boer AJ; Figdor CG; Adema GJ
Cancer Res; 1998 Jun; 58(12):2509-14. PubMed ID: 9635569
[TBL] [Abstract][Full Text] [Related]
20. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens.
Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S
Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
